Mark Cuban's Cost Plus Drugs Aims to Lower Prices for Rare Disease Treatments

Mark Cuban's Cost Plus Drugs initiative is targeting the rare disease treatment market by developing strategies to reduce manufacturing costs for custom medications and n-of-1 gene therapies. Rare diseases often affect small patient populations, making treatments extremely expensive and inaccessible. By streamlining production and reducing overhead costs, Cost Plus Drugs aims to make these specialized therapies more affordable for patients who desperately need them. This approach could transform access to life-saving treatments for individuals with rare genetic and inherited conditions. The initiative represents a significant push to democratize access to personalized medicine and gene therapy options.